Informative value of histological assessment of tissue acquired during aquablation of the prostate.
AquaBeam
Aquablation
Benign prostatic hyperplasia
Histology
Prostate
prostate tissue
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
16
06
2020
accepted:
24
08
2020
pubmed:
10
9
2020
medline:
9
10
2021
entrez:
9
9
2020
Statut:
ppublish
Résumé
To determine the histological validity of the tissue acquired during aquablation of the prostate. Prostatic tissue of 12 patients that consecutively underwent aquablation for benign prostatic enlargement was systematically examined. Histological examination was performed by two experienced uropathologists using a digital slide scanner and slide viewer software (Pannoramic 250 and Case Viewer 2.3, 3D Histech, Hungary). The surface areas of the assessable glands were examined and set in relation to the total surface area of the material available for histology and to the patient's total prostate volume. Examinations were performed analogously in ten consecutive patients undergoing transurethral resection of the prostate (TURP) to facilitate interpretation of the results. Data were analyzed using descriptive statistics. A median of 4.06% (range 1.43-7.5%) of the preoperative total prostate volume (median 64.5 ml (range 40-80 ml)) was obtained for histological examination by aquablation. Due to severe mechanical destruction and fragmentation, only a proportion of 0.43% (0.06-1.79%) of this tissue represented histologically assessable glands. Therefore, roughly 0.017% of the total prostatic volume was available for a reliable histological examination. In comparison, 32.5% (6.67-37.5%) of the total prostate volume was removed by TURP and 22.86% (7.45-40.57%) of this tissue represented informative prostatic glands, corresponding to 7.43% of the total prostate volume. Histological significance of the tissue obtained by aquablation of the prostate is very limited. Costs and effort of the histological examination must, therefore, be weighed critically against the limited informative value.
Identifiants
pubmed: 32902728
doi: 10.1007/s00345-020-03426-2
pii: 10.1007/s00345-020-03426-2
doi:
Substances chimiques
Water
059QF0KO0R
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2043-2047Références
Desai M, Bidair M, Bhojani N, Trainer A, Arther A, Kramolowsky E, Doumanian L, Elterman D, Kaufman RP Jr, Lingeman J, Krambeck A, Eure G, Badlani G, Plante M, Uchio E, Gin G, Goldenberg L, Paterson R, So A, Humphreys M, Roehrborn C, Kaplan S, Motola J, Zorn KC (2019) WATER II (80–150 mL) procedural outcomes. BJU Int 123(1):106–112. https://doi.org/10.1111/bju.14360
doi: 10.1111/bju.14360
pubmed: 29694702
Gilling P, Barber N, Bidair M, Anderson P, Sutton M, Aho T, Kramolowsky E, Thomas A, Cowan B, Kaufman RP Jr, Trainer A, Arther A, Badlani G, Plante M, Desai M, Doumanian L, Te AE, DeGuenther M, Roehrborn C (2018) WATER: a double-blind, randomized, controlled trial of aquablation((R)) vs transurethral resection of the prostate in benign prostatic hyperplasia. J Urol 199(5):1252–1261. https://doi.org/10.1016/j.juro.2017.12.065
doi: 10.1016/j.juro.2017.12.065
pubmed: 29360529
Foster HE, Dahm P, Kohler TS, Lerner LB, Parsons JK, Wilt TJ, McVary KT (2019) Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline amendment 2019. J Urol 202(3):592–598. https://doi.org/10.1097/JU.0000000000000319
doi: 10.1097/JU.0000000000000319
pubmed: 31059668
Gravas S, Cornu, J.N., Gacci, M. et al. (2020) 2020 European Guidelines of the „Management of Non-neurogenic Male LUTS“. Publisher: EAU Guidelines Office. Place published: Arnhem, The Netherlands. https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/#1_3 . Accessed 10 June 2020
Gilling P, Anderson P, Tan A (2017) Aquablation of the prostate for symptomatic benign prostatic hyperplasia: 1-year results. J Urol 197(6):1565–1572. https://doi.org/10.1016/j.juro.2017.01.056
doi: 10.1016/j.juro.2017.01.056
pubmed: 28111300
Gilling P, Reuther R, Kahokehr A, Fraundorfer M (2016) Aquablation—image-guided robot-assisted waterjet ablation of the prostate: initial clinical experience. BJU Int 117(6):923–929. https://doi.org/10.1111/bju.13358
doi: 10.1111/bju.13358
pubmed: 26477826
Yassaie O, Silverman JA, Gilling PJ (2017) Aquablation of the prostate for symptomatic benign prostatic hyperplasia: early results. Curr Urol Rep 18(12):91. https://doi.org/10.1007/s11934-017-0743-2
doi: 10.1007/s11934-017-0743-2
pubmed: 29046995
Zigeuner R, Schips L, Lipsky K, Auprich M, Salfellner M, Rehak P, Pummer K, Hubmer G (2003) Detection of prostate cancer by TURP or open surgery in patients with previously negative transrectal prostate biopsies. Urology 62(5):883–887. https://doi.org/10.1016/s0090-4295(03)00663-0
doi: 10.1016/s0090-4295(03)00663-0
pubmed: 14624913
Biers SM, Oliver HC, King AJ, Adamson AS (2009) Does laser ablation prostatectomy lead to oncological compromise? BJU Int 103(4):454–457. https://doi.org/10.1111/j.1464-410X.2008.08039.x
doi: 10.1111/j.1464-410X.2008.08039.x
pubmed: 18782304
Carmignani L, Macchi A, Ratti D, Finkelberg E, Casellato S, Bozzini G, Maruccia S, Marenghi C, Picozzi S (2015) Are histological findings of thulium laser vapo-enucleation versus transurethral resection of the prostate comparable? Pathol Oncol Res 21(4):1071–1075. https://doi.org/10.1007/s12253-015-9931-x
doi: 10.1007/s12253-015-9931-x
pubmed: 25862670
Nafie S, Dormer J, Khan MA (2017) The significance of histological analysis following laser transurethral resection of the prostate. Int Urol Nephrol 49(8):1343–1346. https://doi.org/10.1007/s11255-017-1617-8
doi: 10.1007/s11255-017-1617-8
pubmed: 28508246
Naspro R, Freschi M, Salonia A, Guazzoni G, Girolamo V, Colombo R, Scattoni V, Rigatti P, Montorsi F (2004) Holmium laser enucleation versus transurethral resection of the prostate. Are histological findings comparable? J Urol 171(3):1203–1206. https://doi.org/10.1097/01.ju.0000099162.12144.8f
doi: 10.1097/01.ju.0000099162.12144.8f
pubmed: 14767301
Abedi AR, Ghiasy S, Fallah-Karkan M, Rahavian A, Allameh F (2020) The management of patients diagnosed with incidental prostate cancer: narrative review. Res Rep Urol 12:105–109. https://doi.org/10.2147/RRU.S245669
doi: 10.2147/RRU.S245669
pubmed: 32215268
pmcid: 7083625
Herlemann A, Wegner K, Roosen A, Buchner A, Weinhold P, Bachmann A, Stief CG, Gratzke C, Magistro G (2017) "Finding the needle in a haystack": oncologic evaluation of patients treated for LUTS with holmium laser enucleation of the prostate (HoLEP) versus transurethral resection of the prostate (TURP). World J Urol 35(11):1777–1782. https://doi.org/10.1007/s00345-017-2048-y
doi: 10.1007/s00345-017-2048-y
pubmed: 28516315
Porcaro AB, Tafuri A, Inverardi D, Amigoni N, Sebben M, Pirozzi M, Processali T, Rizzetto R, Shakir A, Cerrato C, Tiso L, Panunzio A, De Michele M, Brunelli M, Siracusano S, Artibani W (2020) Incidental prostate cancer after transurethral resection of the prostate: analysis of incidence and risk factors in 458 patients. Minerva Urol Nefrol. https://doi.org/10.23736/S0393-2249.19.03564-1
doi: 10.23736/S0393-2249.19.03564-1
pubmed: 32003204
Rosenhammer B, Lausenmeyer EM, Mayr R, Burger M, Eichelberg C (2018) HoLEP provides a higher prostate cancer detection rate compared to bipolar TURP: a matched-pair analysis. World J Urol 36(12):2035–2041. https://doi.org/10.1007/s00345-018-2353-0
doi: 10.1007/s00345-018-2353-0
pubmed: 29858700